U.S. patent application number 16/929186 was filed with the patent office on 2020-10-29 for method for preparing a farnesoid x receptor agonist.
This patent application is currently assigned to DIPHARMA FRANCIS S.r.l.. The applicant listed for this patent is DIPHARMA FRANCIS S.r.l.. Invention is credited to Emanuele ATTOLINO, Luca GIANNOTTI, Renzo GRAZIOSI, Grazia IANNUCCI, Anna IULIANO, Vittorio LUCCHINI, Gabriele RAZZETTI.
Application Number | 20200339622 16/929186 |
Document ID | / |
Family ID | 1000004957791 |
Filed Date | 2020-10-29 |
![](/patent/app/20200339622/US20200339622A1-20201029-C00001.png)
![](/patent/app/20200339622/US20200339622A1-20201029-C00002.png)
![](/patent/app/20200339622/US20200339622A1-20201029-C00003.png)
![](/patent/app/20200339622/US20200339622A1-20201029-C00004.png)
![](/patent/app/20200339622/US20200339622A1-20201029-C00005.png)
![](/patent/app/20200339622/US20200339622A1-20201029-C00006.png)
![](/patent/app/20200339622/US20200339622A1-20201029-C00007.png)
![](/patent/app/20200339622/US20200339622A1-20201029-C00008.png)
![](/patent/app/20200339622/US20200339622A1-20201029-C00009.png)
![](/patent/app/20200339622/US20200339622A1-20201029-C00010.png)
![](/patent/app/20200339622/US20200339622A1-20201029-C00011.png)
View All Diagrams
United States Patent
Application |
20200339622 |
Kind Code |
A1 |
RAZZETTI; Gabriele ; et
al. |
October 29, 2020 |
METHOD FOR PREPARING A FARNESOID X RECEPTOR AGONIST
Abstract
The invention relates to a process for preparing a compound of
formula (I) ##STR00001## in particular obeticholic acid and
intermediates suitable for its synthesis.
Inventors: |
RAZZETTI; Gabriele;
(Baranzate (MI), IT) ; IULIANO; Anna; (Baranzate
(MI), IT) ; GIANNOTTI; Luca; (Baranzate (MI), IT)
; IANNUCCI; Grazia; (Baranzate (MI), IT) ;
ATTOLINO; Emanuele; (Baranzate (MI), IT) ; LUCCHINI;
Vittorio; (Baranzate (MI), IT) ; GRAZIOSI; Renzo;
(Baranzate (MI), IT) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
DIPHARMA FRANCIS S.r.l. |
Baranzate (MI) |
|
IT |
|
|
Assignee: |
DIPHARMA FRANCIS S.r.l.
Baranzate (MI)
IT
|
Family ID: |
1000004957791 |
Appl. No.: |
16/929186 |
Filed: |
July 15, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16090853 |
Oct 3, 2018 |
10752654 |
|
|
PCT/EP2017/057868 |
Apr 3, 2017 |
|
|
|
16929186 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07J 9/005 20130101;
C07J 21/006 20130101 |
International
Class: |
C07J 9/00 20060101
C07J009/00; C07J 21/00 20060101 C07J021/00 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 4, 2016 |
IT |
102016000034216 |
Nov 16, 2016 |
IT |
102016000115948 |
Claims
1. A compound selected from the group consisting of: a compound of
formula (VII): ##STR00030## a compound of formula (VIIa):
##STR00031## a compound of formula (IX): ##STR00032## a compound of
formula (X): ##STR00033## a compound of formula (XII): ##STR00034##
a compound of formula (XIII): ##STR00035## a compound of formula
(XV): ##STR00036## a compound of formula (XVa): ##STR00037## a
compound of formula (XVI) ##STR00038## and a compound of formula
(XVIa) ##STR00039## wherein R.sub.a is hydrogen or an optionally
substituted linear or branched C.sub.1-C.sub.6 alkyl group, or an
optionally substituted aryl; R.sub.b is hydrogen and R.sub.c is OH
or O-PG, wherein PG is an alcohol protecting group; or R.sub.b is
OR.sub.1 and R.sub.c is OR.sub.2; wherein each of R.sub.1 and
R.sub.2, which are the same or different, is a C.sub.1-C.sub.6
alkyl group or R.sub.1 and R.sub.2 taken together form a
--(CH.sub.2).sub.n- chain, wherein n is 2 or 3, wherein the symbol
indicates that the absolute configuration of the double bond can be
(E) or (Z) or a mixture thereof; and the proton H-5 of the
compounds of formula (VII), (IX), (X), (XII), (XIII), (XV), and
(XVI) is in configuration 5.alpha. or 5.beta. or a mixture
thereof.
2. A compound according to claim 1 selected from the group
consisting of:
3-spiro[1,3]dioxolane-(6E/Z)-ethyliden-5.beta.-cholan-24-oic acid
methyl ester; 3-spiro[1,3]dioxolane-6-ethyliden-cholan-24-oic acid;
3-spiro[1,3]dioxolane-(6Z)-ethylidene-5.beta.-cholan-24-oic acid
methyl ester;
3-spiro[1,3]dioxolane-6-ethyliden-7.alpha.-hydroxy-5.beta.-cholan--
24-oic acid methyl ester; 3-oxo-6-ethylidene-5.beta.-cholan-24-oic
acid methyl ester;
3.alpha.-hydroxy-(6Z)-ethylidene-5.beta.-cholan-24-oic acid methyl
ester;
3.alpha.-(2,2-dimethylpropanoyI)-(6Z)-ethylidene-5.beta.-cholan-24-oic
acid methyl ester; and
3.alpha.-(2,2-dimethylpropanoyl)-7.alpha.-hydroxy-(6E)-ethylidene-5.beta.-
-cholan-24-oic acid methyl ester.
3. A pharmaceutical composition comprising a compound of formula
(Ia), which is
6.alpha.-ethyl-3.alpha.,7.alpha.-dihydroxy-5.beta.-cholan-24-oic
acid, also known as 6.alpha.-ethyl-chenodeoxycholic acid,
obeticholic acid or as 6-ECDCA, ##STR00040## and a pharmaceutically
acceptable carrier, wherein the obeticholic acid of formula (Ia)
does not comprise chenodeoxycholic acid of formula 2
##STR00041##
4. The pharmaceutical composition as defined in claim 3, wherein
obeticholic acid of formula (Ia) is obtained starting from
hyodeoxycholic acid having the following formula (II) ##STR00042##
Description
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a divisional of U.S. Ser. No.
16/090,853, dated Oct. 3, 2018, which is a 35 U.S.C. 371 National
Phase Entry Application from PCT/EP2017/057868, filed Apr. 3, 2017,
which claims the benefit of Italian Patent Application Nos.
102016000034216 filed Apr. 4, 2016 and 102016000115948 filed on
Nov. 16, 2016, the disclosures of which are incorporated herein in
their entirety by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to hyodeoxycholic acid and its
intermediates, in particular to their use in a process for
preparing obeticholic acid.
STATE OF THE ART
[0003]
6.alpha.-Ethyl-3.alpha.,7.alpha.-dihydroxy-5.beta.-cholan-24-oic
acid, also known as 6.alpha.-ethyl-chenodeoxycholic acid,
obeticholic acid or as 6-ECDCA, having formula (Ia),
##STR00002##
is an agonist of the farnesoid X receptor (FXR) and is in the
pre-registration phase as active pharmaceutical ingredient for the
treatment of various forms of hepatic cirrhosis, comprising
non-alcoholic steatohepatitis. Obeticholic acid is known from EP 1
392 714, which describes its preparation starting from
chenodeoxycholic acid of formula 2 according to the Scheme 1
reported below:
##STR00003##
[0004] The synthesis for preparing obeticholic acid (Ia) starts
from chenodeoxycholic acid of formula 2, which is an extensively
used product by the pharmaceutical industry and which in turn is
obtained from cholic acid, a major compound of the biliary acid
mixture in bovine bile. The alkylation reaction of the anion of the
protected ketone 3, prepared at -78.degree. C. with BuLi, with EtBr
to give the alkylated intermediate 4, represents the key step of
the process. The yields of this step are low; the reaction
conditions are not suitable for a process on an industrial scale
and the synthesis is of limited efficiency. Subsequently, a new
synthesis for preparing obeticholic acid was described in EP 1 888
614. The process as described in Scheme 2 consists in the
conversion of compound 5 into the protected silyl ether 6. The
preparation of the silyl ether is carried out by treating compound
5 with trimethylsilyl chloride at -78.degree. C. using lithium
diisopropylamide as base. Subsequently, the reaction of the silyl
ether 6 and acetaldehyde in presence of BF.sub.3Et.sub.2O as Lewis
acid provides the .alpha.,.beta.-unsaturated ketone 7 in good
yields. Hydrogenation of the double bond of 7 leads then to the
ketone 8, which once reduced and hydrolyzed provides obeticholic
acid of formula (Ia). This process, which starts as the previous
one from chenodeoxycholic acid 2 and which is definitely more
efficient than the previous one in respect to the yields, still
suffers from the use of expensive bases prepared by using
organolithium derivatives at low temperatures.
##STR00004##
[0005] In addition, the authors of J. Med. Chem 2012, 55, 84-93
underlined different problems of epimerization of the carbon atom
adjacent to the alkyl group of intermediate 8 during the
reduction/alkaline hydrolysis of the methyl ester, while trying to
repeat said process. For this reason, they suggested to substitute
the methyl ester with the benzyl one and to revert the sequence of
hydrogenation and reduction (Scheme 3).
##STR00005##
[0006] In this way, the reduction of the .alpha.,.beta.-unsaturated
ketone 10, obtained starting from chenodeoxycholic acid 2 in the
same manner as already described for compound 7, results in the
protected allylic alcohol 11, which submitted to hydrogenation
provides in a single step obeticholic acid (Ia) without any issue
of epimerization. This optimized synthesis of obeticholic acid of
formula (Ia) starting from chenodeoxycholic acid 2 is more
efficient than all the previous ones, but it still suffers from the
use of expensive bases employed at low temperatures for preparing
the silyl ether derivative, but in particular, as for the other
synthetic processes, for the use of chenodeoxycholic acid 2 as
starting material.
[0007] The above disclosed methods for preparing obeticholic acid
of formula (Ia) have in common the problem to use the same starting
material of animal or vegetable origin: chenodeoxycholic acid 2 is
already used in the synthesis of further active pharmaceutical
ingredients present on the market, and the availability of which,
already difficult as such, may become much more difficult or even
impossible in future.
[0008] In effect, chenodeoxycholic acid 2 is obtained industrially
from cholic acid extracted from bovine bile. Its availability is
limited by the number of the butchered bovines and because cholic
acid is just a fraction of the bovine bile. Furthermore, it is
already widely used for the preparation of ursodeoxycholic acid.
Ursodeoxycholic acid is the most known first line drug for the
treatment of primary biliary cirrhosis in the world.
[0009] CN 105777835, published on Jul. 20, 2016, that is after the
priority date of Apr. 4, 2016 of the present application, discloses
a further process for preparing obeticholic acid of formula (Ia)
starting from 6-oxo-chenodeoxycholic acid alkyl ester 12. Wittig
reaction with ethyltriphenylphosphonium salt in presence of a base
provides the 6-ethylidene chenodeoxycholic acid alkyl ester 13,
which once hydrogenated and deprotected gives obeticholic acid of
formula (Ia) (Scheme 4):
##STR00006##
[0010] 6-oxo-chenodeoxycholic acid methyl ester 12 can be prepared
starting from hyodeoxycholic acid of formula (II) as described in
J. Chem. Soc. Perkin Trans 1, 1990, pages 1-3.
[0011] The inventors of the present invention repeated several
times the Wittig reaction of a compound of formula 12 with a
phosphonium ylide as disclosed in CN 105777835, but they were not
able to obtain the 6-ethylidene chenodeoxycholic acid alkyl ester
of formula 13.
[0012] By considering in details the CN 105777835 procedure, it can
be noted that the phosphonium ylide used in CN 105777835 is both a
strong base and a nucleophile. Thus, in the specific process of CN
105777835, as confirmed by the experiments carried out by inventors
of the present invention, the phosphonium ylide does not react with
the carbonyl group, but likely just deprotonates the hydroxyls at
positions C-3 and/or C-7.
[0013] Thus, it can be safely concluded that the procedures
disclosed in CN 105777835 are not enabling.
[0014] Thus, there is still a need to have an efficient and
economic process for the preparation of obeticholic acid of formula
(Ia), which overcomes the drawbacks of the processes known in the
art and which can be easily carried out on an industrial scale.
Such process should not make use of natural starting materials used
in the synthesis of other active ingredients, nor of reaction
conditions or reagents, which are hardly compatible with synthetic
processes on an industrial level.
SUMMARY OF THE INENTION
[0015] The present invention is directed to the use of
hyodeoxycholic acid of formula (II) for preparing obeticholic acid
of formula (Ia). The process demonstrates to be particularly
advantageous for an industrial application, since hyodeoxycholic
acid of formula (II) is a waste product in the workup of swine
bile.
DETAILED DESCRIPTION OF THE INVENTION
[0016] The inventors of the present invention have found a new and
efficient method for preparing a compound of formula (I), in
particular obeticholic acid of formula (Ia), as herein defined.
This method is of particular advantage on an industrial scale,
which as described below overcomes the synthetic drawbacks of the
prior art and in particular makes use of a raw material of animal
origin, hyodeoxycholic acid of formula (II), which today is
considered only a waste product derived from the workup of swine
bile. Thus, the new method for preparing obeticholic acid of
formula (Ia) is not solely an alternative process for obtaining it,
but, making use of a waste product, represents a considerable
progress in the industrial field.
[0017] The invention provides as a first object a method for the
preparation of a compound of formula (I), wherein the proton in H-5
can be in configuration 5.alpha. or 5.beta. or a mixture thereof,
preferably obeticholic acid of formula (Ia), wherein the proton in
H-5 is in configuration 5.beta.,
##STR00007##
[0018] by a process comprising the use of
3.alpha.,6.alpha.-dihydroxy-5.beta.-cholan-24-oic acid of formula
(II), also known as hyodeoxycholic acid, as starting material,
##STR00008##
[0019] Hyodeoxycholic acid of formula (II) is a secondary biliary
acid, which differs from the more famous chenodeoxycholic acid of
formula 2, as defined above in Scheme 1, because it has the
hydroxylic function in position C-6 instead of C-7 as in
chenodeoxycholic acid of formula 2. Hyodeoxycholic acid is present
in the bile of mammals in varying proportions, but it is the main
constituent of the mixture of cholanic acids present in the swine
bile, wherein it amounts almost to 40% of the total. In the past,
it was used in the synthesis of progesterone. In the 50ies of the
last century, the company Jenapharm of the former Eastern Germany
used it as precursor for the synthesis of steroids. Recently,
however, these syntheses have been abandoned and today
hyodeoxycholic acid is only a waste product of the processing of
porcine bile.
[0020] The authors of the present invention have surprisingly found
that it is possible to obtain a compound of formula (I), in
particular obeticholic acid of formula (Ia), from hyodeoxycholic
acid of formula (II), which otherwise is a waste product, by a
process which does not make use of low temperatures nor of
expensive organometallic bases.
[0021] The problem of using hyodeoxycholic acid of formula (II) for
preparing a compound of formula (I), in particular obeticholic acid
of formula (Ia), is that the ethyl group has to be placed in
position C-6 instead of the hydroxyl group and it is necessary to
oxidize selectively position C-7 in such a way that a hydroxyl
function is introduced in position .alpha..
[0022] In the process of the invention, in the case it is necessary
to protect the hydroxyl function in position C-3 and/or the
carboxylic acid of a compound of the present invention and/or an
intermediate thereof, before carrying out one of the aforementioned
reactions, said chemical group can be protected and deprotected
according to known methods. A thorough discussion for
protection/deprotection steps is provided for example in Greene and
Wuts (Greene, T. W.; Wuts, P. G. M. "Protective Groups in Organic
Synthesis", John Wiley & Sons Inc., 1991) or in Kocienski
(Kocienski, P. J. "Protecting Groups", George Thieme Verlag, 1994).
The hydroxyl group in position C-3 can be protected as ether, for
instance as unsubstituted or substituted benzyl ether, for example
as p-methoxy-benzyl ether, 3,4-dimethylbenzyl ether, benzhydryl
ether; as tetrahydropyranyl ether or as silyl ether, for example as
trimethylsilyl ether, triethylsilyl ether or
tert-butyl-dimethylsilyl ether; or as ester, for example as formyl,
acetyl, pivaloyl or benzoyl ester. Preferably, the hydroxyl group
is protected as tetrahydropyranyl ether, trimethylsilyl ether or
tert-butyl-dimethylsilyl ether, or as formyl, acetyl or pivaloyl
ester.
[0023] Alternatively, the hydroxylic group in position C-3 can be
selectively oxidized to a ketone with N-bromosuccinimide, and the
ketone can be protected as acyclic or cyclic ketal, for example as
dimethylketal, 1,3-dioxolane or 1,3-dioxanes. Once the protection
in position C-3 is no longer necessary, the ketal can be
deprotected to the ketone according to known methods and the
obtained ketone can then be reduced to the hydroxyl group with a
reducing agent, for instance with a hydride reducing agent, for
example NaBH.sub.4 or LiAlH.sub.4.
[0024] The carboxylic acid group can be protected as ester, for
instance as C.sub.1-C.sub.6 alkyl ester, wherein the
C.sub.1-C.sub.6 alkyl group may be optionally substituted by
phenyl. Preferably, the carboxylic acid group is protected as
methyl, ethyl, isopropyl, tent-butyl or benzyl ester. The
protection or deprotection of the carboxylic acid group can be
carried out according to known methods. For instance, the ester can
be prepared by activation of the carboxylate with a good leaving
group as exemplified in Greene and Wuts mentioned above. Removal of
the ester can be carried out according to known methods, for
example cleavage of an ethyl or methyl ester with an acid or base
or a benzyl ester by hydrogenation.
[0025] The authors of the present invention have found that a
preferred process for preparing a compound of formula (I), in
particular obeticholic acid of formula (Ia), starting from
hyodeoxycholic acid of formula (II) is that in which first the
ethyl group is placed in position C-6 instead of the hydroxyl and
then the C-7 position is selectively oxidized.
[0026] The authors of the present invention have found an even more
preferred process for preparing a compound of formula (I), in
particular obeticholic acid of formula (Ia), starting from
hyodeoxycholic acid of formula (II), by a method comprising the
following steps:
[0027] I) oxidation of the hydroxyl group in position C-6 of
hyodeoxycholic acid of formula (II) to the ketone;
[0028] II) reaction of the obtained ketone with an ethylidene
phosphorane, preferably ethylidene triphenylphosphorane; and
[0029] after said reaction with an ethylidene phosphorane,
[0030] III) oxidation in position C-7 in such a way that a hydroxyl
function is introduced in position a; or in alternative to step
III)
[0031] IV) a) the allylic oxidation in position C-7 to a ketone
and
[0032] b) subsequent reduction of the ketone in position C-7 to the
.alpha. hydroxyl with a reducing agent, preferably with a hydride
reducing agent, for example NaBH.sub.4 or LiAlH.sub.4,
[0033] and wherein the hydroxyl group in position C-3 and the
carboxylic acid group present in the compounds described in steps
I)-IV) can be optionally protected.
[0034] Oxidation of the hydroxyl group in step I) can be carried
out under conditions known in the art used for the conversion of a
secondary alcohol to a ketone. For example, conditions and reagents
can be those described below for step c).
[0035] The reaction of the ketone with an ethylidene phosphorane in
step II) can be carried out under Wittig conditions. For example,
conditions and reagents can be those described below for step
d).
[0036] The oxidation in position C-7 in step III) can be carried
out using an oxidizing agent in a solvent. For example, conditions
and reagents can be those described below for step f).
[0037] The allylic oxidation in position C-7 to a ketone in step
IV) a) can be carried out at conditions and with reagents as those
described below for step j).
[0038] Reduction of the ketone to the a hydroxyl in step IV) b) can
be carried out with a hydride reducing agent, for example
NaBH.sub.4 or LiAlH.sub.4, in a solvent, for example an ether.
[0039] Preferably, the reduction is carried out using NaBH.sub.4 in
a solvent, for example a dialkyl ether or tetrahydrofuran
(THF).
[0040] A further object of the present invention is hyodeoxycholic
acid of formula (II) for use in a process for preparing a compound
of formula (I), in particular obeticholic acid of formula (Ia).
[0041] According to the process of the invention, a key compound in
the preparation of a compound of formula (I), in particular of
formula (Ia), is a compound of formula (VII)
##STR00009##
[0042] wherein R.sub.a is hydrogen or an optionally substituted
linear or branched C.sub.1-C.sub.6 alkyl group, or an optionally
substituted aryl;
[0043] R.sub.b is hydrogen and R.sub.c is OH or O-PG, wherein PG is
an alcohol protecting group as defined above, for instance an
unsubstituted or substituted benzyl ether, a tetrahydropyranyl
ether, a silyl ether, or an ester; or, alternatively,
[0044] R.sub.b is OR.sub.1 and R.sub.c is OR.sub.2;
[0045] wherein each of R.sub.1 and R.sub.2, which may be the same
or different, is a C.sub.1-C.sub.6 alkyl group, or R.sub.1 and
R.sub.2 taken together form a --(CH.sub.2).sub.n- chain, wherein n
can be 2 or 3,
[0046] and wherein the symbol indicates that the absolute
configuration of the double bond can be (E) or (Z) or a mixture
thereof; and wherein the H-5 proton can be either in configuration
5.alpha. or 5.beta. or a mixture thereof.
[0047] Preferably, the alcohol protecting group is
tetrahydropyranyl ether, trimethylsilyl ether or
tert-butyl-dimethylsilyl ether, or a formyl, acetyl or pivaloyl
ester.
[0048] Preferably, a compound of formula (VII) is a compound of
formula (VIIa), wherein the proton H-5 is in configuration
5.beta.,
##STR00010##
[0049] and wherein R.sub.a, R.sub.b, R.sub.c and the symbol are as
defined above.
[0050] A C.sub.1-C.sub.6 alkyl group, which can be linear or
branched, is typically a C.sub.1-C.sub.4 alkyl group, for instance
methyl, ethyl, propyl, isopropyl, or butyl, isobutyl, tent-butyl,
optionally substituted by one or more substituents, preferably from
one to three substituents, which may be the same or different, such
as halogen, for example chlorine or fluorine, or aryl, for example
phenyl.
[0051] An aryl group may be, for example, a phenyl or naphthyl
group, typically phenyl. Said aryl group may be optionally
substituted by one to three substituents independently selected
from a linear or branched C.sub.1-C.sub.4 alkyl group, which in
turn may be optionally substituted by one to three halogen atoms,
typically fluorine; a hydroxy group; a C.sub.1-C.sub.4 alkoxy
group, for example methoxy; a halogen atom, such as bromine or
chlorine; a cyano group; and a nitro group.
[0052] Preferably, the substituent R.sub.a in a compound of formula
(VII) or (VIIa) is H, methyl or benzyl.
[0053] According to an aspect of the invention, a compound of
formula (VII), as single isomer or as mixture of isomers, and in
particular a compound of formula (VIIa), as defined above, and
wherein R.sub.b is OR.sub.1 and R.sub.c is OR.sub.2 as defined
above, can be obtained by a process comprising the following steps:
[0054] a) selective oxidation of the hydroxyl group in position C-3
of a compound of formula (III)
##STR00011##
[0055] wherein R is an optionally substituted linear or branched
C.sub.1-C.sub.6 alkyl group, or an optionally substituted aryl
group, to obtain a compound of formula (IV):
##STR00012##
[0056] wherein R is as defined above; [0057] b) protection of the
ketone group in C-3 position of a compound of formula (IV) to
obtain a compound of formula (V):
##STR00013##
[0058] wherein R.sub.1, R.sub.2 and R are as defined above; [0059]
c) oxidation of the hydroxyl group in position C-6 of a compound of
formula (V), and optional saponification of the ester group, to
obtain a compound of formula (VI):
##STR00014##
[0060] wherein R.sub.a, R.sub.1 and R.sub.2 are as defined above;
and [0061] d) reaction of a compound of formula (VI) with a
compound of formula (VIII):
##STR00015##
[0062] wherein Ph is phenyl, to obtain a compound of formula (VII);
and in particular a compound of formula (VIIa).
[0063] A compound of formula (III) is a known compound, or can be
obtained in an advantageous manner from hyodeoxycholic acid of
formula (II) by [0064] e) protection of the carboxylic function of
the hyodeoxycholic acid of formula (II) in order to obtain a
compound of formula (III):
##STR00016##
[0065] wherein R is as defined above.
[0066] In step a) of the synthesis, the protected ester of
hyodeoxycholic acid of formula (III) is oxidized selectively at the
C-3 position providing a compound of formula (IV). The selective
oxidation at the C-3 required an optimization study. Indeed, the
oxidation of the compound of formula (III) has been studied under
different experimental conditions, for example under the Swem
conditions, such as DMSO activated with (COCl).sub.2, using
KMnO.sub.4 or TEMPO as catalyst in presence of NaClO or
NaClO.sub.2, but in all cases only mixtures of products with mono
or double oxidations of positions C-3 and C-6 were obtained.
However, it was found that it is possible to obtain a compound of
formula (IV) with high selectivity carrying out the oxidation with
N-bromosuccinimide in a solvent. The oxidation reaction can be
performed in a polar aprotic solvent selected, for example, in the
group comprising dimethyl sulfoxide; acetonitrile;
dimethylformamide or dimethylacetamide; a ketone, for example
acetone or methylethylketone; water; or a mixture of two or more,
preferably two or three, of said solvents.
[0067] According to a preferred aspect of the invention, the
reaction can be carried out in presence of a mixture of
water/acetone. Said reaction can be performed at a temperature
comprised from about -10.degree. C. to 50.degree. C., preferably
from about 0.degree. C. to 10.degree. C.
[0068] A preferred aspect of the invention is the oxidation of a
compound of formula (III) with N-bromosuccinimide to obtain a
compound of formula (IV).
[0069] According to step b), the ketone group at C-3 of a compound
of formula (IV) is protected before oxidation at C-6.
[0070] The protection step can be performed according to known
methods, for example in presence of a C.sub.1-C.sub.4 alcohol, of a
diol, for example ethylene glycol or propylene glycol, or of vinyl
ether and in presence of an acid catalyst, in order to provide a
protected compound of formula (V), wherein R.sub.1 and R.sub.2 are
as defined above. Preferably, the substituents R.sub.1 and R.sub.2
of a compound of formula (V) taken together form a
--(CH.sub.2).sub.n- chain, wherein n is 2.
[0071] According to step c), thanks to the protection of the ketone
function at position C-3, the compound of formula (V) can be thus
selectively oxidized at C-6, with following optional saponification
of the ester group, to give a compound of formula (VI), wherein
R.sub.a, R.sub.1 and R.sub.2 are as defined above.
[0072] The oxidation reaction can be carried out under conditions
known in the art used for the conversion of a secondary alcohol to
a ketone. The reaction is preferably carried out at a pH value
between about 4 and 10. These conditions permit to avoid the
hydrolysis of the ester or acetal functionalities, which do occur
at strongly basic or strongly acidic pH values. Preferably, the
oxidation reaction is conducted in the presence of the catalyst
TEMPO using NaClO or NaClO.sub.2 as oxidizing agents in a
solvent.
[0073] The solvent can be a polar aprotic solvent, such as
dimethylformamide, dimethylsulfoxide or acetonitrile; an ethereal
solvent, for example diethyl ether, methyl tent-butyl ether or
tetrahydrofuran; a ketone, for example methyl ethyl ketone, methyl
isobutyl ketone or acetone; an apolar aprotic solvent, for example
hexane, heptane, toluene or xylene; an ester, for example an
acetate of a linear or branched C.sub.1-C.sub.5 alcohol, preferably
ethyl acetate; a chlorinated solvent, such as dichloromethane
(CH.sub.2Cl.sub.2), chloroform or chlorobenzene; or water, or an
aqueous solution of an inorganic salt able to generate a pH between
about 7 and 10; or a mixture of two or more, typically two or
three, of the above solvents. Preferably, the solvent is a biphasic
system consisting of an organic solvent, preferably
dichloromethane, and an aqueous solution at a pH between about 7
and 10.
[0074] The optional saponification of a compound of formula (VI)
can be carried out according known methods.
[0075] According to step d), a compound of formula (VI) can be
converted into a compound of formula (VII), preferably into a
compound of formula (VIIa), as defined above, for example by a
process carried out under Wittig conditions using a phosphorus
ylide of formula (VIII), wherein Ph is phenyl, in a solvent.
##STR00017##
[0076] The ylide of formula (VIII) can be simply prepared by
treating an ethyltriphenylphosphonium salt with a strong base as
well known to a person skilled in the art.
[0077] A strong base can be for example a strong organic base, for
instance an alkaline metal alkoxide, preferably potassium
tent-butylate or sodium tent-butylate; NaH; or lithium
diisopropylamide (LDA).
[0078] The Wittig reaction can be performed at a temperature
comprising between -10.degree. C. and the reflux temperature of the
solvent, preferably between about 0.degree. C. and 30.degree. C.
During the conversion of a compound of formula (VI) into a compound
of formula (VII) a partial epimerization of the C-5 of a compound
formula (VI) can occur in the experimental conditions of the Wittig
reaction. A compound of formula (VIIa), wherein the proton H-5 is
in configuration 5.beta., can be isolated for example by
crystallization, typically in a linear or branched C.sub.1-C.sub.5
alcohol, for instance methanol, ethanol isopropanol, n-butanol,
iso-butanol or n-pentanol, preferably isopropanol.
[0079] In step e) of the synthesis, hyodeoxycholic acid of formula
(II) is converted into a derivative with a protected carboxylic
acid function, such as an ester of formula (III). Such protection
can be carried out according to known methods in the art, for
example in the field of steroid chemistry, by esterification of
cholanic acids.
[0080] The inventors of the present invention have found that a
compound of formula (VII), preferably of formula (VIIa), is a key
compound for the preparation of a compound of formula (I), and
preferably of obeticholic acid of formula (Ia).
[0081] A compound of formula (VII), in particular of formula
(VIIa), which are new compounds, are further embodiments of the
invention, as well as a compound of formula (VIIa) for use in a
method for preparation of obeticholic acid of formula (Ia).
[0082] A further embodiment of the present invention is a compound
of (VII) or of formula (VIIa) selected from:
[0083] 3-spiro[1,3]dioxolane-(6E/Z)-ethyliden-5.beta.-cholan-24-oic
acid methyl ester;
[0084] 3-spiro[1,3]dioxolane-6-ethyliden-cholan-24-oic acid;
[0085] 3-spiro[1,3]dioxolane-(6Z)-ethylidene-5.beta.-cholan-24-oic
acid methyl ester; and [0086]
3.alpha.-(2,2-dimethylpropanoyl)-(6Z)-ethylidene-5.beta.-cholan-24-oic
acid methyl ester.
[0087] A compound of formula (VII), wherein R.sub.b is OR.sub.1 and
R.sub.c is OR.sub.2 as defined above, can be converted into a
compound of formula (I), as defined above, by a process further
comprising: [0088] f) stereoselective allylic oxidation of a
compound of formula (VII) to obtain a compound of formula (IX):
##STR00018##
[0088] wherein R.sub.a, R.sub.1 and R.sub.2 and the symbol are as
defined above; [0089] g) the removal of the protection at C-3
position of a compound of formula (IX) to obtain a compound of
formula (X):
##STR00019##
[0089] wherein the symbol and R.sub.a are as defined above; [0090]
h) the stereoselective reduction of the ketone group at C-3
position of a compound of formula (X) to obtain a compound of
formula (XI):
##STR00020##
[0090] wherein the symbol and R.sub.a are as defined above; and
[0091] i) the hydrogenation of a compound of formula (XI) to obtain
a compound of formula (I); or [0092] j) allylic oxidation in
position C-7 of a compound of formula (VII) to obtain a compound of
formula (XII):
##STR00021##
[0092] wherein the symbol , R.sub.a, R.sub.1 and R.sub.2 are as
defined above; [0093] k) the removal of the protection at C-3
position of a compound of formula (XII) to obtain a compound of
formula (XIII):
##STR00022##
[0093] wherein the symbol and R.sub.a are as defined above and
optional saponification; [0094] l) the hydrogenation of a compound
of formula (XIII) to obtain a compound of formula (XIV):
##STR00023##
[0094] wherein R.sub.a is as defined above; and [0095] m) reduction
of a compound of formula (XIV) to obtain a compound of formula
(I).
[0096] In particular, a compound of formula (VII), and preferably a
compound of (VIIa), can be converted into a compound of formula
(I), and preferably into a compound of formula (Ia), as defined
above, by a process further comprising: [0097] n) the removal of
the protection at C-3 position of a compound of formula (VII), or
(VIIa), to obtain a compound of formula (XV), or (XVa),
respectively,
##STR00024##
[0097] wherein the symbol and R.sub.a are as defined above; [0098]
o) the stereoselective reduction of the ketone group at the C-3
position of a compound of formula (XV), or (XVa), to obtain a
compound of formula (XVI), or (XVIa), respectively, and optional
saponification of the ester function:
##STR00025##
[0098] wherein the symbol and R.sub.a are as defined above; and
[0099] p) the allylic oxidation in position C-7 in a compound of
formula (XVI) or (XVIa), and optional saponification of the ester
function, to obtain a compound of formula (XI) or (XIa),
respectively:
##STR00026##
[0099] wherein the symbol and R.sub.a are as defined above; [0100]
q) the hydrogenation of a compound of formula (XI), or (XIa), to
obtain a compound of formula (I), as defined above, or obeticholic
acid of formula (Ia); or [0101] r) the protection of the hydroxyl
group at C-3 position and allylic oxidation of position C-7 of a
compound of formula (XVI), or (XVIa), or the allylic oxidation of
position C-7 of a compound of formula (VII), or (VIIa), and
optional saponification of the ester function, to obtain a compound
of formula (XVII), or (XVIIa)
##STR00027##
[0101] wherein the symbol and R.sub.a, R.sub.b and R.sub.c are as
defined above; [0102] s) the oxidation of the hydroxyl group in
position C-7 to the keto group and the removal of the protection at
C-3 of a compound of formula (XVII) or (XVIIa) to obtain a compound
of formula (XVIII) or (XVIIIa):
##STR00028##
[0102] wherein the symbol and R.sub.a are as defined above; [0103]
t) the hydrogenation and reduction of a compound of formula (XVIII)
or (XVIIIa) to obtain a compound of formula (I) or (Ia).
[0104] In a preferred aspect of the invention a compound of formula
(VIIa) is a key compound in the process for preparation obeticholic
acid of formula (Ia), which can be preferably obtained according to
the synthetic sequence from n) to q) or r) to t).
[0105] The stereoselective allylic oxidation of a compound of
formula (VII) according to step f), or of a compound of formula
(XVI) or (XVIa) according to step p) or of a compound of formula
(VII), (VIIa), (XVII), or (XVIIa) according to step r) can be
carried out using an oxidizing agent in a solvent.
[0106] An oxidizing agent can be for example SeO.sub.2, MnO.sub.2
or a peroxyester, for example tent-butyl perbenzoic acid, in
presence of a Cu(I) salt or of Pd, Ru or Rh complexes, or a
hydroperoxide, for example tent-butyl hydroperoxide, catalyzed by
Cu/Al oxides.
[0107] The allylic oxidation can be performed at a temperature
comprised from about -10.degree. C. to the reflux temperature of
the solvent, preferably between about 20.degree. C. and 80.degree.
C.
[0108] The solvent may be a polar aprotic solvent, such as
dimethylformamide, dimethylsulfoxide or acetonitrile; an ethereal
solvent, for example methyl tent-butyl ether, tetrahydrofuran or
dioxane; a ketone, e.g. methyl ethyl ketone, methyl isobutyl ketone
or acetone; an apolar aprotic solvent, for example hexane, heptane,
toluene or xylene; an ester, for example an acetate of a linear or
branched C.sub.1-C.sub.5 alcohol, preferably ethyl acetate; a
chlorinated solvent, such as dichloromethane (CH.sub.2Cl.sub.2),
chloroform or chlorobenzene; or water; or a mixture of two or more,
typically two or three, of the above solvents.
[0109] According to step g), k) or n), the acetal protection of a
compound of formula (IX), of formula (XII), of formula (VII) or of
formula (VIIa) can be removed providing a compound of formula (X),
of formula (XIII), of formula (XV) or of formula (XVa),
respectively, wherein R.sub.a is as defined above.
[0110] The reaction can be performed in an acidic aqueous solution,
according to methods known to the skilled person, used for the
hydrolysis of acetals
[0111] The compounds of formula (IX), (X), (XII), (XIII), (XV),
(XVa), (XVI), (XVIa), (XVII), or of formula (XVIIa) are new and are
a further embodiment of the present invention.
[0112] A further embodiment of the present invention is a compound
of formula (IX), (X), (XII), (XIII), (XV), (XVa), (XVI), (XVIa),
(XVII), or of formula (XVIIa), in particular a compound selected
from:
[0113]
3-spiro[1,3]dioxolane-6-ethyliden-7.alpha.-hydroxy-5.beta.-cholan-2-
4-oic acid methyl ester;
[0114] 3-oxo-6-ethylidene-5.beta.-cholan-24-oic acid methyl
ester;
[0115] 3.alpha.-hydroxy-(6Z)-ethylidene-5.beta.-cholan-24-oic acid
methyl ester;
[0116]
3.alpha.-(2,2-dimethylpropanoyl)-7.alpha.-hydroxy-(6E)-ethylidene-5-
.beta.-cholan-24-oic acid methyl ester.
[0117] Another embodiment of the present invention is the use of a
compound of formula (IX), (X), (XII), (XIII), (XV), (XVI) or (XVII)
for the preparation of a compound of formula (I) and the same
compounds for the use in a method for the preparation of a compound
of formula (I).
[0118] A further embodiment of the present invention is the use of
a compound of formula (XVa), (XVIa) or (XVIIa) for the preparation
of obeticholic acid of formula (Ia), and the same compound for the
use in a method for the preparation of obeticholic acid of formula
(Ia).
[0119] The stereoselective reduction of the ketone group at C-3 in
a compound of formula (X), of formula (XV) or of formula (XVa)
according to steps h) or o), or of a compound of formula (XVIII) or
(XVIIIa) according to steps t) can be carried out with a hydride
reducing agent, for example NaBH.sub.4 or LiAlH.sub.4, in a
solvent, for example an ether. According to step m), a compound of
formula (XIV) can be reduced by a reducing step analogous to the
ones reported in Chemistry Letters, 1996, 5, 335-336, or in
Steroids, 2006, 71(6), 469-475, with a hydride reducing agent, for
example NaBH.sub.4 or LiAlH.sub.4, in a solvent, for example an
ether, as indicated above.
[0120] Preferably, the reduction in steps h), m) or o) can be
carried out using NaBH.sub.4 in tetrahydrofuran (THF).
[0121] The hydrogenation of a compound of formula (XI), or of
formula (XIa) to obtain a compound of formula (I), in particular of
obeticholic acid of formula (Ia), according to the steps i) and q),
or of formula (XIII) according to the step l), or of a compound of
formula (XVIII) or (XVIIIa) according to steps t) can be carried
out according to known methods, in particular as described in J.
Med. Chem 2012, 55, 84-93, in a mixture of THF/methanol using Pd/C
as catalyst. Optionally, a crude product of formula (XIa) as
obtained after the hydrogenation can be purified by crystallization
in order to obtain pure obeticholic acid of formula (Ia). For
example, hydrogenation in step l) of a compound of formula (XIII)
to obtain a compound of formula (XIV), as defined above, can be
performed as reported in EP 1 888 614.
[0122] The hydrogenation of a compound of formula (XI), (XIa) or
(XIII) can be carried out by catalytic hydrogenation in presence of
homogenous or heterogeneous metal catalyst, for example a Pd, Pt,
Ni, Rh or Ru catalyst, preferably a Pd catalyst.
[0123] In case of an heterogeneous metal catalyst, the catalyst is
preferably placed on an inert support, such as, for example,
carbon, barium hydroxide, alumina, calcium carbonate; preferably
charcoal. The concentration of the metal on the support may vary
between about 1% and 30%, preferably between about 5% and 20%.
[0124] The employed hydrogen pressure may vary from about 1 atm to
40 atm, preferably from about 1 atm to 10 atm.
[0125] The molar quantity of the used catalyst, referred to a
compound of formula (XIII), is comprised between about 0.1 and 10%,
preferably between about 0.5 and 5%.
[0126] The reaction can be carried out in presence of an organic
solvent selected, for example, from a polar aprotic solvent, such
as dimethylformamide, dimethylacetamide acetonitrile or
dimethylsulfoxide; an acyclic or cyclic ethereal solvent, typically
tetrahydrofuran or methyl tent-butyl ether; a chlorinated solvent,
typically dichloromethane; an apolar aprotic solvent, for example
toluene or hexane; a polar protic solvent, for example a linear or
branched C.sub.1-C.sub.6 alcohol, in particular methanol, ethanol,
isopropanol or butanol; an ester, for example ethyl acetate,
isopropyl acetate or butyl acetate; a linear or branched
C.sub.3-C.sub.7 ketone, for example acetone, methyl ethyl ketone,
methyl isobutyl ketone; a carboxylic acid, for example acetic acid
or propionic acid; or water; or a mixture of two or more, typically
two or three, of the above solvents.
[0127] Alternatively, the hydrogenation reactions can be carried
out in a solution of a mineral acid or base, for example
hydrochloric acid or sulfuric acid, or sodium or potassium
hydroxide; or a mixture of them with one, two or three organic
solvents indicated above.
[0128] Said hydrogenation reactions can be performed at a
temperature comprised from about 0.degree. C. and the reflux
temperature of the solvent, preferably between about 25.degree. C.
and the reflux temperature.
[0129] The hydrogenation reaction of a compound of formula (XI),
(XIa) or (XIII) can be carried out by a hydrogen transfer reaction,
using a homogeneous or heterogeneous metal catalyst, for example
those defined above, and a hydrogen donor. The latter can be
selected for example from the group comprising cyclohexene;
cyclohexadiene; methylcyclohexene; limonene; dipentene; menthene;
hydrazine; phosphinic acid or its derivatives, such as sodium
hypophosphite; indoline; ascorbic acid; formic acid or its sodium
or ammonium salts; and secondary alcohols, for example isopropanol.
A preferred hydrogen donor is ammonium formate.
[0130] The molar ratio between the hydrogen donor and the compound
of formula (XIII) can be between about 1.5 and 50, preferably
between about 1.5 and 10.
[0131] The reduction by the hydrogen transfer reaction can be
carried out in presence of an organic solvent, selected for example
from one of the above mentioned solvents.
[0132] The allylic oxidation in position C-7 in a compound of
formula (VII) according to step j) to obtain a compound of formula
(XII), as defined above, can be performed in the conditions as
described for an allylic oxidation described previously, which
results immediately from the alkene to the enone instead of the
allylic alcohol, as described for example in Synthesis 2013, 45,
2201-2221. Preferably, the oxidation can be carried out using metal
oxidizing systems based on Cr, Cu, Se, Rh, Co, Ru, Pd and in
absence of a metallic oxidant in the presence of NaClO,
NaClO.sub.2, NaIO.sub.4, O.sub.2 or an organic peroxide, for
example tert-butylhydroperoxide.
[0133] The protection of the hydroxyl group at C-3 position in step
r) and the removal of the protecting group in step s) can be
performed according to known methods. For example, the hydroxyl
group can be protected as ester by reaction with an acyl chloride
or anhydride in presence of a base, for example pyridine or
trimethylamine (TEA). The cleavage of the ester can be performed
for example by treatment with a base, for example sodium hydroxide.
Alternatively, the hydroxyl group can be protected as ether by
reaction with dihydropyran, unsubstituted or substituted benzyl
halide or a silyl halide, wherein the halide can be chloride or
bromide. The cleavage of the tetrahydropyran or the silyl ether can
be performed for example by treatment with an acid, and the benzyl
protecting group by hydrogenation.
[0134] The oxidation of the hydroxyl in position C-7 to its keto
derivative of step s) can be performed according to known methods.
For example, the hydroxyl group can oxidized with IBX or an IBX
adduct, for instance as described in Mendeleev Comm. 2012, 22,
129-131 or in PCT/EP2016/070883.
[0135] A further embodiment of the present invention is directed to
a pharmaceutical composition comprising a compound of formula (Ia),
thus being
6.alpha.-ethyl-3.alpha.,7.alpha.-dihydroxy-5.beta.-cholan-24-oic
acid, also known as 6.alpha.-ethyl-chenodeoxycholic acid,
obeticholic acid or as 6-ECDCA,
##STR00029##
[0136] and a pharmaceutically acceptable carrier, wherein the
obeticholic acid of formula (Ia) does not comprise chenodeoxycholic
acid of formula 2. The pharmaceutical composition can be prepared
according to known methods.
[0137] Chenodeoxycholic acid of formula 2 and obeticholic acid of
formula (Ia) have similar physicochemical properties and as
asserted by Dr. Melissa Rewolinski under C.F.R. .sctn. 1.132 during
the prosecution of U.S. Pat. No. 9,238,673 signed on Sep. 25, 2015,
a separation by chromatography, even by HPLC, would be
impractical.
[0138] The process of preparing obeticholic acid of formula (Ia)
according to the present invention is consequently of particular
advantage, since it does not make use of chenodeoxycholic acid of
formula 2. Accordingly, obeticholic acid of formula (Ia), as
obtained by the process of the present invention, is free from
chenodeoxycholic acid 2. Therefore, there is no need to separate
said products.
[0139] The following examples further illustrate the invention.
EXAMPLE 1
Synthesis of 3.alpha.-Oxo-6.alpha.-Hydroxy-5.beta.-Cholan-24-Oic
Acid Methyl Ester of Formula (IV) with R.dbd.Me
[0140] Hyodeoxycholic acid methyl ester (16.0 g, 39.4 mmol) of
formula (III) is dissolved in a solution of 160 mL of acetone and
80 mL of water in a 250 mL three-neck flask comprising a
thermometer and a magnetic stirrer. The obtained solution is cooled
down to a temperature between 0 and 5.degree. C. and
N-bromosuccinimide (11.9 g, 67.0 mmol) is added portionwise as
solid. The reaction mixture is stirred at a temperature between 0
and 5.degree. C. for 3 hours, then treated with 5% NaOH solution
(70 mL) and stirred for an additional hour. The mixture is then
concentrated under reduced pressure and extracted with toluene. The
obtained organic layer is first washed with a 5% NaOH solution,
then with a saturated solution of NaCl. The obtained organic phase
is used as such in the subsequent reaction. An aliquot of the
solution is concentrated to dryness and analyzed.
[0141] .sup.1H-NMR (CDCl.sub.3, 400 MHz, 24.degree. C.) .delta.:
0.65 (3H, s); 0.89 (3H, d, J=6.4 Hz); 0.97 (3H, s); 2.36-1.07 (27H,
m); 3.62 (3H, s); 4.04 (1H, m).
[0142] .sup.13C-NMR (CDCl.sub.3, 100 MHz, 24.degree. C.) .delta.:
213.20, 174.71, 67.36, 56.08, 55.89, 51.49, 50.21, 42.80, 40.19,
39.80, 37.10, 37.05, 36.13, 36.10, 35.28, 34.50, 34.19, 30.99,
30.90, 28.07, 24.15, 22.82, 21.07, 18.24, 12.03.
EXAMPLE 2
Synthesis of
3-Spiro[1,3]Dioxolane-6.alpha.-Hydroxy-5.beta.-Cholan-24-Oic Acid
Methyl Ester of Formula (V) with R.dbd.Me; R.sub.1 and R.sub.2
Taken Together Form a --(CH.sub.2).sub.n-Chain, wherein n is 2.
[0143] The solution as obtained in Example 1 is treated with
ethylene glycol (10.9 g, 175 mmol) and paratoluenesulfonic acid
(0.0750 g, 0.395 mmol) in a 250 mL three-neck flask comprising a
thermometer, a magnetic stirrer and a Dean-Stark apparatus. The
solution is heated to reflux to remove the water/toluene azeotrope
and stirred for 2 hours. At the end of the reaction the mixture is
cooled down to about 20.degree. C. and stirred for at least a
further hour to allow the product to precipitate. The mixture is
filtered off and the solid washed with water and pre-cooled diethyl
ether. Then, the solid is dried under reduced pressure to obtain
the 3-spiro[1,3]dioxolane-6.alpha.-hydroxy-5.beta.-cholan-24-oic
acid methyl ester of formula (V) (14.9 g, 33.2 mmol) with a yield
of 85%, calculated from the hyodeoxycholic acid methyl ester of
formula (III). The product is analyzed by .sup.1H and .sup.13C-NMR
and results to be sufficiently pure to be used in the next step
without any further purification.
[0144] .sup.1H-NMR (CDCl.sub.3, 400 MHz, 24.degree. C.) .delta.:
0.63 (3H, s); 0.90 (3H, d, J=6.4 Hz); 0.92 (3H, s); 1.04-2.49 (26H,
m); 3.70 (3H, s); 3.94 (4H, m); 4.05 (1H, m).
[0145] .sup.13C-NMR (CDCl.sub.3, 100 MHz, 24.degree. C.) .delta.:
174.79, 109.71, 67.83, 64.20, 64.09, 56.13, 55.86, 51.49, 47.26,
42.82, 39.91, 39.15, 35.88, 35.31, 34.63, 34.58, 34.38, 31.02,
30.93, 30.13, 28.68, 28.09, 24.15, 23.25, 20.97, 18.23, 12.02.
EXAMPLE 3
Synthesis of the 3-Spiro[1,3]Dioxolane-6-Oxo-5.beta.-Cholan-24-Oic
Acid Methyl Ester of Formula (VI) with R.sub.a.dbd.Me; R.sub.1 and
R.sub.2 Taken Together Form a --(CH.sub.2).sub.n-Chain, wherein n
is 2.
[0146] 3-Spiro[1,3]dioxolane-6.alpha.-hydroxy-5.beta.-cholan-24-oic
acid methyl ester of formula (V), as prepared in Example 2 (14.9 g,
33.2 mmol), KBr (1.97 g, 16.6 mmol), Bu.sub.4NBr (0.640 g, 1.99
mmol), Na.sub.2HPO.sub.42H.sub.2O (0.71 g, 4.0 mmol) and
NaH.sub.2PO.sub.4H.sub.2O (0.79 g, 0.57 mmol) are dissolved in a
mixture composed by CH.sub.2Cl.sub.2 (150 mL) and water (40 mL) in
a 500 mL three-neck flask comprising a mechanical stirrer,
thermometer and a dropping funnel. The obtained biphasic mixture is
cooled down to 0.degree. C. and treated with TEMPO (0.16 mg, 0.99
mmol) and a 1.9% solution of NaOCl (143.0 mL, 36.49 mmol) keeping
the temperature below 5.degree. C. Once the addition is completed,
the reaction mixture is stirred for 30 minutes and then treated
with MeOH. After 15 minutes the organic phase is then separated and
washed with a solution of 5% HCl (2.times.50 mL), a solution of 5%
NaOH (2.times.50 mL) and with a saturated NaCl solution (50 mL) and
finally dried over anhydrous Na.sub.2SO.sub.4. After filtration,
the solution is concentrated under reduced pressure providing the
3-spiro[1,3]dioxolane-6-oxo-5.beta.-cholan-24-oic acid methyl ester
of formula (VI) (14.5 g, 32.4 mmol) with a yield of 97%.
[0147] The product was analyzed by .sup.1H and .sup.13C-NMR and
resulted to be sufficiently pure to be used in the next step
without any further purification.
[0148] .sup.1H-NMR (CDCl.sub.3, 200 MHz, 24.degree. C.) .delta.:
0.71 (3H, s); 0.91 (3H, s); 0.97 (3H, d, J=6.2 Hz); 1.04-2.49 (26H,
m); 3.71 (3H, s); 3.97 (4H, m).
[0149] .sup.13C-NMR (CDCl.sub.3, 50 MHz, 24.degree. C.) .delta.:
213.60, 174.77, 108.23, 64.68 (2C), 58.73, 57.17, 56.12, 51.82,
43.44, 43.09, 39.97, 39.67, 38.23, 37.26, 35.62, 34.76, 33.69,
31.38, 31.27, 30.55, 28.35, 24.30, 23.34, 21.49, 18.61, 12.36.
EXAMPLE 4
Synthesis of the
3-Spiro[1,3]Dioxolane-(6E/Z)-Ethyliden-5.beta.-Cholan-24-Oic Acid
Methyl Ester of Formula (VII) with R.sub.a.dbd.Me; R.sub.1 and
R.sub.2 Taken Together Form a --(CH.sub.2).sub.n- Chain, Wherein n
is 2.
[0150] Ethyltriphenylphosphonium bromide (10.80 g, 29.14 mmol) is
suspended under inert atmosphere in 70 mL of anhydrous THF in a 250
mL three-neck flask comprising a dropping funnel, a thermometer and
a magnetic stirrer. The mixture is cooled down to 0.degree. C.,
solid t-BuOK (3.20 g, 28.6 mmol) is added portionwise and the
mixture is stirred for 40 minutes. Then, a solution of
3-spiro[1,3]dioxolane-6-oxo-5.beta.-cholan-24-oic acid methyl ester
of formula (VI) (5 g, 11.2 mmol), prepared as described in Example
3, in 30 mL of THF is added. The reaction mixture is stirred for 18
hours and the temperature was raised within the same time to room
temperature. At the end of the reaction the mixture is treated with
water (1.0 g, 55 mmol) and concentrated under reduced pressure. The
obtained residue is purified by silica gel chromatography
(toluene/acetone 90/10), providing the
3-spiro[1,3]dioxolane-(6E/Z)-ethyliden-5.beta.-cholan-24-oic acid
methyl ester of formula (VII) (2.82 g, 6.16 mmol) as solid
amorphous diastereoisomeric mixture (E)/(Z).
[0151] .sup.1H-NMR (CDCl.sub.3, 200 MHz, 24.degree. C.) .delta.:
(diagnostic signals, mixture E/Z) 0.61-0.63 (9H, m); 0.80 (3H, m),
0.90 (6H, d, J=6.4 Hz); 1.59-1.53 (6H, m); 3.64 (6H, s); 3.92 (8H,
m); 4.87 (1H, q, J=6.8 Hz), 5.18 (1H, q, J=6.6 Hz).
[0152] .sup.13C-NMR (CDCl.sub.3, 50 MHz, 24.degree. C.) .delta.:
(mixture E/Z) 174.14, 139.13, 117.00, 112.99, 109.53, 109.00,
63.87, 63.79, 56.12, 55.52, 54.42, 51.13, 48.36, 43.14, 42.49,
39.94, 39.62, 37.42, 36.80, 36.53, 35.43, 35.35, 35.03, 34.76,
33.90, 33.52, 33.11, 30.68, 29.76, 27.83, 23.88, 22.41, 21.22,
20.83, 17.97, 12.55, 12.13, 11.83, 11.78, 11.40.
EXAMPLE 5
Synthesis of 3-Spiro[1,3]Dioxolane-6-Oxo-Cholan-24-Oic Acid of
Formula (VI) with R.sub.a.dbd.H; R.sub.1 and R.sub.2 Taken Together
Form a --(CH.sub.2).sub.n- Chain, wherein n is 2.
[0153] 3-spiro[1,3]dioxolane-6-oxo-5.beta.-cholan-24-oic acid
methyl ester of formula (VI) (11.0 g, 24.6 mmol), as prepared as in
Example 3, is dissolved in 22 mL of MeOH in a 100 mL three-neck
flask comprising a dropping funnel, a thermometer and a magnetic
stirrer. The mixture is cooled down to 0.degree. C. and treated
with a solution of 30% of NaOH (11 mL). The reaction mixture is
stirred for 18 hours at room temperature, then cooled down to
0.degree. C. and treated with HCl 37% until reaching a pH of 2. The
methanol is evaporated under reduced pressure, the aqueous phase is
extracted with CH.sub.2Cl.sub.2 and the organic phase dried over
anhydrous Na.sub.2SO.sub.4 and concentrated to residue.
3-Spiro[1,3]dioxolane-6-oxo-cholan-24-oic acid of formula (VI)
(10.9 g, 24.0 mmol) is obtained in a quantitative yield.
[0154] .sup.1H-NMR (CDCl.sub.3, 200 MHz, 24.degree. C.) .delta.:
0.65 (3H, s); 0.74 (3H, s); 0.91 (3H, d, J=6.2 Hz); 1.04-2.57 (26H,
m); 3.97 (4H, m).
[0155] .sup.13C-NMR (CDCl.sub.3, 50 MHz, 24.degree. C.) .delta.:
211.71, 180.11, 109.36, 64.56, 64.48, 57.02, 56.33, 56.05, 53.84,
46.93, 43.37, 41.22, 39.82, 38.19, 36.03, 35.58, 31.35, 31.22,
31.04, 30.14, 28.26, 24.29, 21.80, 18.57, 12.84, 12.40.
EXAMPLE 6
Synthesis of 3-Spiro[1,3]Dioxolane-6-Ethyliden-Cholan-24-Oic Acid
of Formula (VII) with R.sub.a=H; R.sub.1 and R.sub.2 Taken Together
Form a --(CH.sub.2).sub.n- Chain, wherein n is 2.
[0156] Ethyltriphenylphosphonium bromide (42.70 g, 115.1 mmol) is
suspended under inert atmosphere in anhydrous THF (340 mL) in a 250
mL three-neck flask comprising a dropping funnel, a thermometer and
a mechanical stirrer. The mixture is cooled down to 0.degree. C.
and t-BuOK (12.64 g, 113.9 mmol) is added portionwise as solid and
stirred for 40 minutes, then treated with a solution of
3-spiro[1,3]dioxolane-6-oxo-cholan-24-oic acid of formula (VI)
(10.9 g, 25.3 mmol), prepared as described in Example 5, in 85 mL
of THF. The reaction mixture is stirred for 18 hours at room
temperature, then treated with acetic acid (8.30 g, 139 mmol).
After 30 minutes of further stirring, the mixture is filtered and
the obtained solution concentrated under reduced pressure. The
residue is then purified by crystallization from a solution of
methanol:water 2:1. After filtration and drying
3-spiro[1,3]dioxolane-6-ethyliden-cholan-24-oic acid of formula
(VII) (7.50 g, 16.9 mmol) is obtained with a yield of 67%.
[0157] .sup.1H-NMR (CDCl.sub.3, 200 Mhz, 24.degree. C.) .delta.:
(diagnostic signals) 0.64 (6H, s); 0.92 (3H, d, J=6.4 Hz); 1.59
(3H, d, J=6.8 Hz); 3.93 (4H, s); 4.89 (1H, q, J=6.8 Hz).
[0158] .sup.13C-NMR (CDCl.sub.3, 50 Mhz, 24.degree. C.) .delta.:
180.49, 139.80, 113.69, 110.32, 64.50, 64.42, 56.77, 56.16, 55.07,
49.03, 43.18, 40.28, 38.09, 37.19, 35.99, 35.66, 34.55, 33.73,
31.40, 31.25, 31.12, 28.45, 24.53, 21.86, 18.59, 13.17, 12.50,
12.04.
EXAMPLE 7
Synthesis of
3-Spiro[1,3]Dioxolane-6-Ethyliden-7.alpha.-Hydroxy-5.beta.-Cholan-24-Oic
Acid Methyl Ester of Formula (IX) with R.dbd.Me; R.sub.1 and
R.sub.2 Taken Together Form a --(CH.sub.2).sub.n- Chain, wherein n
is 2.
[0159] 3-Spiro[1,3]dioxolane-6-ethyliden-5.beta.-cholan-24-oic acid
methyl ester of formula (VII) (2.50 g, 5.46 mmol), as prepared as
in Example 4, is dissolved in 15 mL of dioxane in a 50 mL two-neck
flask comprising a thermometer and a magnetic stirrer and the
obtained solution is treated with SeO.sub.2 (1.51 g, 13.6 mmol).
The reaction mixture is stirred for 20 hours, then diluted with 5
mL of a solution of HCl at 5% and stirred for a further hour, then
filtered on celite. The solution is concentrated under reduced
pressure and diluted with 20 mL of CH.sub.2Cl.sub.2. The organic
phase is washed with a saturated solution of NaCl and concentrated
under reduced pressure. Then, the residue is purified by silica gel
chromatography (CH.sub.2Cl.sub.2: acetone 95:5), providing
3-spiro[1,3]dioxolane-6-ethyliden-7.alpha.-hydroxy-5.beta.-cholan-24-oic
acid methyl ester of formula (IX) (1.20 g, 2.53 mmol)
diastereoisomeric mixture (E)/(Z) as amorphous solid with a yield
of 47%.
[0160] .sup.1H-NMR (CDCl.sub.3, 200 MHz, 24.degree. C.) .delta.:
(diagnostic signals of the mixture E/Z) 0.62 (3H, s); 0.63 (3H, s);
0.64 (3H, s); 0.77 (3H, s); 0.91 (6H, d, 6,2 Hz); 1.61 (3H, d,
J=6.8 Hz), 1.65 (3H, dd, J1=7.0 Hz, J2=1.4 Hz), 3.65 (6H, s); 3.92
(8H, m); 4.55 (2H, d, J=2.0 Hz); 5.05 (1H, q, J=6.8 Hz), 5.50 (1H,
q, J=6.6 Hz).
[0161] .sup.13C-NMR (CDCl.sub.3, 50 MHz, 24.degree. C.) .delta.:
(mixture E/Z) 174.91, 142.30 (E), 141.58 (Z), 123.97 (E), 117.29
(Z), 110.11 (Z), 109.39, 64.55, 64.46, 56.02, 51.78, 50.58, 50.45,
46.31, 43.11, 42.61, 40.83, 40.37, 39.80, 35.71, 33.62, 31.34,
28.45, 23.92, 22.77, 21.65, 18.60, 12.74, 12.18, 12.05, 10.97.
[0162] .sup.1H-NMR (CDCl.sub.3, 200 MHz, 24.degree. C.) .delta.:
(diagnostic signals of isomer Z) 0.63 (3H, s); 0.77 (3H, s); 0.91
(3H, d, 6,2 Hz); 1.65 (3H, dd, J1=7.0 Hz, J2=1.4 Hz), 3.65 (3H, s);
3.92 (4H, m); 4.55 (1H, d, J=2.0 Hz); 5.05 (1H, q, J=6.8 Hz).
[0163] .sup.13C-NMR (CDCl.sub.3, 50 MHz, 24.degree. C.) .delta.:
(isomer Z) 174.89, 141.63, 117.16, 110.10 (C-3), 66.29 (C-7), 64.52
(2C), 56.02, 51.77, 50.56, 46.27, 43.09, 42.58, 40.83, 39.77,
38.02, 35.71 (2C), 33.61, 31.33 (3C), 28.44, 23.90, 21.65, 18.58,
12.94, 12.18, 10.96.
EXAMPLE 8
Synthesis of
3.alpha.,7.alpha.-Dihydroxy-6-Ethyliden-5.beta.-Cholan-24-Oic Acid
Methyl Ester of Formula (XI) with R.sub.a.dbd.Me
[0164]
3-Spiro[1,3]dioxolane-6-ethyliden-7a-hydroxy-5.beta.-cholan-24-oic
acid methyl ester of formula (IX) (1.10 g, 2.32 mmol), obtained as
described in Example 7, and p-toluenesulfonic acid (110 mg, 0.580
mmol) are dissolved in 25 mL of a mixture of 99:1 acetone:water in
a 100 mL two-neck flask comprising a thermometer, a reflux
condenser and a magnetic stirrer. The reaction mixture is stirred
for 9 hours at about 25.degree. C., then treated with 5 mL of an
aqueous solution of NaHCO.sub.3 at 5% and concentrated to
residue.
[0165] The raw mixture is extracted with CH.sub.2Cl.sub.2 (10 mL)
and the organic phase washed with a saturated solution of NaCl
(2.times.5 mL), dried over Na.sub.2SO.sub.4 and filtered.
3-Oxo-6-ethyliden-7.alpha.-hydroxy-5.beta.-cholan-24-oic acid
methyl ester (X) in configuration (Z) (900 mg) is obtained after
evaporation of the solvent under reduced pressure. NaBH.sub.4 (53.0
mg, 1.39 mmol) is suspended under inert atmosphere in 2 mL of a
mixture of THF:MeOH 9:1 at 0.degree. C. in a 10 mL two-neck flask
comprising a thermometer and a reflux condenser and the
3-oxo-6-ethyliden-7.alpha.-hydroxy-5.beta.-cholan-24-oic acid
methyl ester of formula (X) (400 mg) is added once the formation of
hydrogen is terminated. The reaction mixture is stirred for further
3 hours, then treated with 1 mL of a solution of HCl at 10% and
diluted with 10 mL of CH.sub.2Cl.sub.2. The organic phase is washed
with a saturated solution of NaCl (5 mL), dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure.
The obtained residue is purified by silica gel chromatography
(toluene:acetone 90:10) providing 130 mg (0.30 mmol) of
3.alpha.,7.alpha.-dihydroxy-6-ethyliden-5.beta.-cholan-24-oic acid
methyl ester of formula (XI) with a yield of 30%.
[0166] .sup.1H-NMR (CDCl.sub.3, 200 MHz, 24.degree. C.) .delta.:
(diagnostic signals) 0.61 (3H, s); 0.64 (3H, s); 0.90 (3H, d, J=6.0
Hz); 1.65 (3H, dd, J1=7.0 Hz, J2=1.4 Hz); 3.61 (1H, m); 3.64 (3H,
s); 4.55 (1H, d, J=2.0 Hz); 5.05 (1H, q, J=6.8 Hz).
[0167] .sup.13C-NMR (CDCl.sub.3, 50 MHz, 24.degree. C.) .delta.:
174.98, 141.48, 117.53, 71.96 (C-3), 66.40 (C-7), 56.09, 51.82,
50.63, 46.66, 43.51, 43.15, 40.87, 39.79, 38.09, 36.82, 35.74,
33.86, 31.54, 31.37 (2C), 28.47, 23.92, 21.73, 18.60, 12.97, 12.20,
11.82.
EXAMPLE 9
Synthesis of
3.alpha.,7.alpha.-Dihydroxy-6-Ethyliden-5.beta.-Cholan-24-Oic Acid
of Formula (XI) with R.sub.a.dbd.H
[0168]
3.alpha.,7.alpha.-Dihydroxy-6-ethyliden-5.beta.-cholan-24-oic acid
methyl ester of formula (XI), with R.sub.a.dbd.Me as obtained in
Example 8, (80 mg, 0.19 mmol) is dissolved in 3 mL of a mixture of
MeOH:NaOH at 30% 2:1 in a 10 mL one-neck flask. The mixture is
stirred for 18 hours, then acidified with aqueous HCl until
reaching pH=1 and extracted several times with CH2Cl2. The obtained
organic phase is dried over anhydrous Na2SO4, filtered and
concentrated under reduced pressure.
3.alpha.,7.alpha.-Dihydroxy-6-ethyliden-5.beta.-cholan-24-oic acid
of formula (XI), wherein R.sub.a is H, (75 mg, 0.18 mmol) is
obtained as a white crystalline solid with a yield of 96%.
[0169] .sup.1H-NMR (CDCl.sub.3, 200 MHz, 24.degree. C.) .delta.:
(diagnostic signals) 0.65 (3H, s); 0.69 (3H, s); 0.95 (3H, d, J=6.2
Hz); 1.67 (3H, dd, J1=6.8 Hz, J2=1.4 Hz); 3.58 (1H, m); 4.55 (1H,
d, J=0.6 Hz); 5.05 (1H, q, J=6.8 Hz).
[0170] .sup.13C-NMR (CD.sub.3OD, 50 MHz, 24.degree. C.) .delta.:
176.92, 142.15, 116.07, 71.33, 65.58, 56.27, 50.44, 46.57, 43.30,
42.82, 41.01, 39.86, 37.79, 36.79, 35.70, 33.25, 31.30, 30.97,
30.90, 28.16, 23.49, 21.53, 17.84, 11.67, 11.34, 11.02.
EXAMPLE 10
Synthesis of
3-Spiro[1,3]Dioxolan-(6Z)-Ethylidene-5.beta.-Cholan-24-Oic Acid
Methyl Ester of Formula (VIIa)
[0171] Ethyltriphenylphosphonium bromide (98.0 g, 0.264 mol) is
suspended in THF (650 mL) under inert atmosphere is a one liter
three-neck reactor equipped with a reflux condenser, thermometer
and a mechanical stirrer. The mixture is cooled down to 0.degree.
C. and treated with solid t-BuOK (29.0 g, 0.258 mol) added
portionwise. The suspension is stirred for 60 minutes, then treated
with a solution of
3-spiro[1,3]dioxolane-6-oxo-5.beta.-cholan-24-oic acid methyl ester
of formula (VI) (25 g, 0.056 mol), obtained as described in Example
3, in 150 mL of THF. At the end of the reaction the mixture is
diluted with water (120 mL) and the organic phase is separated and
concentrated under reduced pressure. The residue is extracted with
heptane (2.times.100 mL), the combined organic phases are washed
with water (100 mL) and concentrated under reduced pressure. The so
obtained raw material is crystallized from isopropanol. After
filtration and drying
3-spiro[1,3]dioxolan-(6Z)-ethylidene-5.beta.-cholan-24-oic acid
methyl ester of formula (VIIa) (4.6 g, 0.010 mol) is obtained with
a yield of 18%.
[0172] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.: 5.20 (1 H, q,
J=6.6 Hz), 3.98-3.88 (4H, m), 3.66 (3H, s), 2.62-2.54 (1H, m),
1.04-2.4 (26H, m), 1.56 (3H, d, J=6.9 Hz), 0.91 (3H, d, J=6.0 Hz),
0.81 (3H, s), 0.62 (3H, s).
EXAMPLE 11
Synthesis of 3-oxo-6-Ethylidene-5.beta.-Cholan-24-Oic Acid Methyl
Ester of Formula (XVa)
[0173] 3-Spiro[1,3]dioxolan-6-ethylidene-5.beta.-cholan-24-oic acid
methyl ester of formula (VIIa), obtained as described in Example
10, (1.30 g, 2.83 mmol) is suspended under nitrogen in a mixture of
acetone (15 mL) and HCl 5% (5 mL) in a 50 mL three-neck flask
comprising a thermometer, a reflux condenser. The reaction mixture
is stirred with a magnetic stirrer at room temperature for 6 hours,
then the acetone is distilled off and the residual suspension is
diluted with H.sub.2O (10 mL). The obtained solid is filtered,
washed with H.sub.2O (3.times.10 mL) and dried under vacuum at
50.degree. C. for 4 hours. 1.18 g of
3-oxo-(6Z)-ethylidene-5.beta.-cholan-24-oic acid methyl ester of
formula (XVa) are obtained in quantitative yields.
[0174] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.: 5.25 (1 H, q,
J=6.6 Hz), 3.66 (3H, s), 2.78-1.04 (26H, m), 1.53 (3H, d, J=6.6
Hz), 0.92 (3H, d, J=6.3 Hz), 0.88 (3H, s), 0.66 (3H, s).
EXAMPLE 12
Synthesis of 3.alpha.-Hydroxy-(6Z)-Ethylidene-5.beta.-Cholan-24-Oic
Acid Methyl Ester of Formula (XVIa)
[0175] 3-Oxo-6-ethylidene-5.beta.-cholan-24-oic acid methyl ester
of formula (XVa), obtained as described in Example 11, (1.18 g,
2.85 mmol) is dissolved at room temperature and under nitrogen in a
mixture of methanol (6 mL) and THF (6 mL) in a 50 mL three-neck
flask equipped with a thermometer and a reflux condenser. The
obtained solution is cooled down to 0.degree. C., and NaBH.sub.4
(0.108 g, 2.85 mmol) is added portion wise as solid. The solution
is stirred at 0.degree. C. for 30 minutes, then poured into a
solution of 1 M HCl (10 mL) at 0.degree. C. The obtained mixture is
stirred for 15 minutes and then extracted with CH.sub.2Cl.sub.2
(2.times.10 mL). The combined organic phases are concentrated under
reduced pressure and the obtained residue is purified by silica gel
chromatography (toluene:acetone=95:5) providing 900 of
3.alpha.-hydroxy-(6Z)-ethylidene-5.beta.-cholan-24-oic acid methyl
ester of formula (XVIa) with a yield of 76%.
[0176] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.: 5.20 (1 H, q,
J=6.9 Hz), 3.54-3.72 (4H, m), 2.40-1.00 (26H, m), 1.54 (3H, d,
J=6.6 Hz), 0.91 (3H, d, J=6.3 Hz), 0.78 (3H, s), 0.63 (3H, s).
EXAMPLE 13
Synthesis of
3.alpha.,7.alpha.-Dihydroxy-(6E)-Ethylidene-5.beta.-Cholan-24-Oic
Acid Methyl Ester of Formula (XIa)
[0177] 3.alpha.-Hydroxy-6-ethylidene-5.beta.-cholan-24-oic acid
methyl ester of formula (XVIa), obtained in Example 12, (0.9 g,
2.17 mmol) is dissolved in dioxane (15 mL) at room temperature and
under nitrogen atmosphere in a 50 mL three-neck flask equipped with
a thermometer and a reflux condenser. Water (60 .mu.l) and
SeO.sub.2 (289 mg, 2.60 mmol) are added and the reaction mixture is
heated to 60.degree. C. After stirring for 1 hour, the solution is
concentrated under reduced pressure. Then, the residue is portioned
between CH.sub.2Cl.sub.2 (10 mL) and H.sub.2O (10 mL), the phases
are separated and the organic phase concentrated under reduced
pressure. The so obtained raw material is purified by silica gel
chromatography (CH.sub.2Cl.sub.2:acetone=80:20), giving 500 mg of
3.alpha.,7.alpha.-dihydroxy-(6E)-ethylidene-5.beta.-cholan-24-oic
acid methyl ester of formula (XIa) with a yield of 50%.
[0178] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.: 5.49 (1 H, q,
J=6.9 Hz), 3.96-3.86 (1H, m), 3.65 (3H, s), 3.56-3.44 (1H, m),
2.40-1.00 (24H, m), 1.59 (3H, d, J=6.9 Hz), 0.91 (3H, d, J=6.0 Hz),
0.73 (3H, s), 0.62 (3H, s).
EXAMPLE 14
Synthesis of
3.alpha.,7.alpha.-Dihydroxy-(6E)-Ethylidene-5.beta.-Cholan-24-Oic
Acid of Formula (XIa)
[0179]
3.alpha.,7.alpha.-Dihydroxy-(6E)-ethylidene-5.beta.-cholan-24-oic
acid methyl ester of formula (Ma), obtained in Example 13, (500 mg,
1.16 mmol) is dissolved at room temperature and under nitrogen in
methanol (5 mL) in a 50 mL three-neck flask equipped with a
thermometer and a reflux condenser. NaOH 30% (687 mg, 5.15 mmol) is
added and the reaction is carried out under stirring for 16 hours
at room temperature. The solution is then acidified with HCl 37% to
pH 1, diluted with water (10 mL) and extracted with
CH.sub.2Cl.sub.2 (2.times.5 mL). The combined organic phases are
concentrated under reduced pressure and the obtained residue is
purified by silica gel chromatography (CH.sub.2Cl.sub.2:MeOH=90:10)
giving 300 mg of
3.alpha.,7.alpha.-dihydroxy-(6E)-ethylidene-5.beta.-cholan-24-oic
acid of formula (XIa) with a yield of 62%.
[0180] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.: 5.49 (1 H, q,
J=6.9 Hz), 3.92-3.96 (1H, m), 3.46-3.56(1H, m), 2.40-1.00 (24H, m),
1.59 (3H, d, 6.6 J=Hz), 0.92 (3H, d, 6.0 J=Hz), 0.73 (3H, s), 0.63
(3H, s).
EXAMPLE 15
Synthesis of
3.alpha.-(2,2-Dimethylpropanoyl)-(6Z)-Ethylidene-5.beta.-Cholan-24-Oic
Acid Methyl Ester of Formula (VIIa)
[0181] 3.38 g (8.11 mmol) of
3.alpha.-hydroxy-(6Z)-ethylidene-5.beta.-cholan-24-oic acid methyl
ester of formula (XVIa), as obtained in Example 12, are dissolved
in THF (20 ml) at room temperature and under nitrogen atmosphere in
a 50 mL three-neck flask equipped with a thermometer and a reflux
condenser. TEA (3.4 ml; 24.3 mmol) and pivaloyl chloride (2 ml,
16.2 mmol) are added and the reaction mixture is heated to reflux.
After stirring for 16 hours, the solution is concentrated under
reduced pressure. Then, the residue is diluted with EtOAc (30 ml)
and washed with HCl 5% (20 ml), NaHCO.sub.3 saturated solution (20
ml) and H.sub.2O (20 ml). The organic phase is concentrated under
reduced pressure giving 3.17 g of
3.alpha.-(2,2-dimethylpropanoyl)-(6Z)-ethylidene-5.beta.-cholan-24-oic
acid methyl ester of formula (VIIa) with a yield of 78%.
[0182] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.: 5.20 (1 H, q,
J=6.9 Hz), 4.80-4.66 (1H, m), 3.66 (3H, s), 2.40-1.00 (38H, m),
0.91 (3H, d, J=6.3 Hz), 0.79 (3H, s), 0.63 (3H, s).
EXAMPLE 16
Synthesis of
3.alpha.-(2,2-Dimethylpropanoyl)-7.alpha.-Hydroxy-(6E)-Ethylidene-5.beta.-
-Cholan-24-Oic Acid Methyl Ester of Formula (XVIIa)
[0183] 0.5 g (1 mmol) of the
3.alpha.-(2,2-dimethylpropanoyl)-(6Z)-ethylidene-5.beta.-cholan-24-oic
acid methyl ester of formula (VIIa), as obtained in Example 15, are
dissolved in dioxane (7.5 ml) at room temperature and under
nitrogen atmosphere in a 50 mL three-neck flask equipped with a
thermometer and a reflux condenser. Water (20 .mu.l) and SeO.sub.2
(133 mg, 1.2 mmol) are added and the reaction mixture is heated to
60.degree. C. and stirred for 2 hour, then concentrated under
reduced pressure. The so obtained raw material is purified by
silica gel chromatography (toluene:acetone=97.5:2.5), giving 100 mg
of
3.alpha.-(2,2-dimethylpropanoyl)-7.alpha.-hydroxy-(6E)-ethylidene-5.beta.-
-cholan-24-oic acid methyl ester of formula (XVIIa) with a yield of
20%.
[0184] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.: 5.49 (1 H, q,
J=6.9 Hz), 4.66-4.54 (1H, m), 3.94 (1H, s), 3.64 (3H, s), 2.40-1.00
(37H, m), 0.91 (3H, d, J=6.30 Hz), 0.75 (3H, s), 0.63 (3H, s).
EXAMPLE 17
Synthesis of
3.alpha.-Hydroxy-7-Oxo-(6E)-Ethylidene-5.beta.-Cholan-24-Oic Acid
of Formula (XVIIIa) and its Conversion into Obeticholic Acid of
Formula (Ia)
[0185] 0.1 g (0.19 mmol) of
3.alpha.-(2,2-dimethylpropanoyl)-7.alpha.-hydroxy-(6E)-ethylidene-5.beta.-
-cholan-24-oic acid methyl ester of formula (XVIIa), as obtained in
Example 16, is dissolved in THF (1 ml) at room temperature and
under nitrogen atmosphere in a 20 mL two-neck flask.
2-Iodoxybenzoic acid (IBX) adduct with quinoline (80 mg, 0.20
mmol), prepared as disclosed in PCT/EP2016/070883, are added and
the reaction mixture is heated to 50.degree. C. and stirred for 2
hour, then filtered and concentrated under reduced pressure. Then,
the residue is diluted with CH.sub.2Cl.sub.2 (2 ml) and washed with
HCl 5% (2 ml), NaHCO.sub.3 saturated solution (2 ml) and H.sub.2O
(2 ml). The organic phase is concentrated under reduced pressure
giving 105 mg of raw material that is dissolved in methanol (2 ml)
and treated with NaOH 30% (0.5 ml). The solution is stirred for 48
hours, then acidified with HCl 37% until reaching pH 1 and
concentrated under reduced pressure. The obtained residue is
purified by silica gel chromatography
(CH.sub.2Cl.sub.2:acetone=95:5) giving 43 mg of
3.alpha.-hydroxy-7-oxo-(6E)-ethylidene-5.beta.-cholan-24-oic acid
of formula (XVIIIa) with a yield of 53%.
[0186] .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.: 6.18 (1 H, q,
J=6.9 Hz), 3.70-3.58 (1H, m), 2.60-1.10 (29H, m), 1.00 (3H, s),
0.94 (3H, d, J=6.3 Hz), 0.64 (3H, s).
[0187] 3.alpha.-Hydroxy-7-oxo-(6E)-ethylidene-5.beta.-cholan-24-oic
acid of formula (XVIIIa) can be converted into obeticholic acid of
formula (Ia) according to known methods. For example,
3.alpha.-hydroxy-7-oxo-(6E)-ethylidene-5.beta.-cholan-24-oic acid
of formula (XVIIIa) can be hydrogenated with Pd/C and hydrogen gas,
e.g. according to the teaching of EP 1 888 614 or U.S. Pat. No.
9,238,673, and reduced with NaBH.sub.4 as described in Example 12
of the present invention.
[0188] Alternatively, the
3.alpha.-hydroxy-7-oxo-(6E)-ethylidene-5.beta.-cholan-24-oic acid
of formula (XVIIIa) can be converted into its C.sub.1-C.sub.6 alkyl
ester according to the methods disclosed above, and then converted
into obeticholic acid of formula (Ia) by hydrogenation of the
(6E)-ethylidene group, reduction of the 7-oxo group and
deprotection of the ester according to known methods.
* * * * *